Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
6Customers
2Debt Items
8Related Chains
Source-Backed Evidence Depth
Compass Therapeutics, Inc. (CMPX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
3Distinct source URLs
8High confidence
0.780Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Compass Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
ABL-BIO-INC
ABL-BIO-INC
92%
We have licensed exclusive global rights to tovecimig, outside of South Korea, from ABL Bio, Inc.
ELPISCIENCE-BIOPHARMACEUTICALS-CO-LIMITED
ELPISCIENCE-BIOPHARMACEUTICALS-CO-LIMITED
92%
China rights were out-licensed from us to Elpiscience Biopharmaceuticals Co., Limited
HANDOK-PHARMACEUTICALS-INC
HANDOK-PHARMACEUTICALS-INC
92%
South Korean rights are held by Handok Pharmaceuticals, Inc.
ABL-BIO
ABL-BIO
90%
ABL Bio received a $5 million upfront payment and a $6 million milestone payment
ADIMAB-LLC
ADIMAB-LLC
90%
We are required to make payments upon achievement of development milestones that, as of December 31, 2025, amounted to $3.5 million
Reciprocal relationship from CBIO graph: ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be …
Compass Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
B-RILEY-SECURITIES-INC
B-RILEY-SECURITIES-INC
62%
t expenses 6,068 5,023 1,045 Total research and development expenses $ 42,342 $ 38,120 $ 4,222 General and administrative expenses General and administrative expenses increased by $2.9 million from $…
GUGGENHEIM-SECURITIES-LLC
GUGGENHEIM-SECURITIES-LLC
62%
ufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our therapies and any future product candidates. Our net losses were $66 million…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
CTX-10726 10,216 — 10,216 Other research and development expenses 7,465 6,068 1,397 Total research and development expenses $ 55,969 $ 42,342 $ 13,627 General and administrative expenses General and …
OLIVIA-VENTURES-INC
OLIVIA-VENTURES-INC
62%
Item 13. Certain Relationships and Related Transactions, and Director Independence 139 Item 14. Principal Accountant Fees and Services 139 PART IV Item 15. Exhibits and Financial Statement Schedules …
Q-SMALLER-REPORTING-COMPANY
Q-SMALLER-REPORTING-COMPANY
62%
sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of our therapies and any future product candidates. Our net losses were $18.3 mill…
TRIGR-THERAPEUTICS-INC
TRIGR-THERAPEUTICS-INC
62%
dustry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing;…
Compass Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CMPX-DEBT
Debt stack $9.8M
90%
Market cache reports total debt of $9.8M.
CMPX-DEBT-8725
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Compass Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Compass Therapeutics, Inc..
Compass Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CMPX-OWNER-TANG-CAPITAL-MANAGEMENT-LLC
Tang Capital Management, LLC
90%
13F overlay lists Tang Capital Management, LLC as top holder; 10 tracked holders.
Compass Therapeutics, Inc. Extended Supply Chain Network
